|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
BORYUNG PHARM CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name BORYUNG PHARM CO.,LTD. Headquarters BORYUNG BLDG., 66-21, WONNAM-DONG, JONGNO-GU, SEOUL; Seoul; Seoul; 110750 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: Deloitte Touche Tohmatsu (2011) Incorporation Date: November 11, 1963 Total Employees: 1,015 Tel: 02-708-8000 |
|
Company Description |
| Business volume increased over the year-earlier period with active sales of main product Gelfos M, and newly started goods such as HAV vaccine.Profitability decreased from the year-earlier periods with expanding R&D expenses and sales and admin expenses though sales cost ratio fell by reducing royalty fee of ox bezoar.New hypertension medicine Kanav launched in March 2011 has considerably contributed to the sales growth under the constantly expanding hypertension market. Business growth will be maintained | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues decreased with -2.51%, from KRW 156,679,107 thousands to KRW 152,750,253 thousands. Operating result decreased from KRW 7,934,347 thousands to KRW 2,018,718 thousands which means -74.56% change. The results of the period decreased -17.44% reaching KRW 4,319,082 thousands at the end of the period against KRW 5,231,758 thousands last year. Return on equity (Net income/Total equity) went from 3.76% to 3.05%, the Return On Asset (Net income / Total Asset) went from 2.08% to 1.61% and the Net Profit Margin (Net Income/Net Sales) went from 3.34% to 2.83% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 89.85% compared to 80.86% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.47 to 1.44 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 H1 (non-cons) |
2011 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
268,866,105 |
262,386,266 |
| ||
Current Assets |
154,676,454 |
149,728,371 |
| ||
Total Liabilities |
127,249,047 |
124,416,758 |
| ||
Shareholders Equity |
141,617,058 |
137,969,507 |
| ||
Current Liabilities |
107,766,834 |
106,842,036 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
152,750,253 |
308,005,547 |
| ||
Operational Profit (Loss) |
2,018,718 |
6,659,709 |
| ||
Net Profit (Loss) |
4,319,082 |
6,178,117 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
1.61% |
2.35% |
| ||
Return on Equity (ROE) |
3.05% |
4.48% |
| ||
Return on Sales (ROS) |
2.83% |
2.01% |
| ||
Return on Capital |
2.68% |
3.97% |
| ||
Gross Profit Margin |
42.08% |
41.03% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.99x |
2.06x |
| ||
Asset Turnover |
0.57x |
1.17x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
5,153,057 |
2,493,618 |
| ||
EBITDA |
2,615,274 |
7,398,456 |
| ||
Bookvalue (BV) |
125,263,296 |
124,658,530 |
| Liquidity Ratios | ||
| ||
Current Ratio |
143.53% |
140.14% |
| ||
Quick ratio |
106.39% |
99.17% |
| ||
Doom's day ratio |
8.67% |
1.84% |
| ||
Cash Flow to Debt |
5.73% |
0.21% |
| Leverage Ratios | ||
| ||
Leverage ratio |
189.85% |
190.18% |
| ||
Interest Coverage Ratio |
278.05% |
415.74% |
| ||
Debt to equity |
89.85% |
90.18% |
| ||
Debt to total assets |
47.33% |
47.42% |
| ||
Long Term Debt to Capital |
12.09% |
11.3% |
| Market ratios | ||
| ||
Price/Book Ratio |
0.63 |
0.81 |
| Trend Ratios | ||
| ||
Revenue Trend |
97.49% |
102.34% |
| ||
Net Income Trend |
82.56% |
45.26% |
| ||
 |